V
Volker Heinemann
Researcher at Ludwig Maximilian University of Munich
Publications - 682
Citations - 24634
Volker Heinemann is an academic researcher from Ludwig Maximilian University of Munich. The author has contributed to research in topics: Colorectal cancer & Cetuximab. The author has an hindex of 71, co-authored 587 publications receiving 20104 citations. Previous affiliations of Volker Heinemann include Klinikum der Universität München & German Cancer Research Center.
Papers
More filters
Journal ArticleDOI
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Volker Heinemann,Ludwig Fischer von Weikersthal,Thomas Decker,Alexander Kiani,Ursula Vehling-Kaiser,Salah-Eddin Al-Batran,Tobias Heintges,Christian A. Lerchenmuller,Christoph Kahl,G. Seipelt,Frank Kullmann,Martina Stauch,Werner Scheithauer,Jörg Hielscher,Michael Scholz,Sebastian Müller,Hartmut Link,Norbert Niederle,Andreas Rost,Heinz-Gert Höffkes,Markus Moehler,Reinhard Udo Lindig,Dominik Paul Modest,Lisa Rossius,Thomas Kirchner,Andreas Jung,Sebastian Stintzing +26 more
TL;DR: The association with longer overall survival suggests that FOLFIRI plus cetuximab could be the preferred first-line regimen for patients with KRAS exon 2 wild-type metastatic colorectal cancer.
Journal ArticleDOI
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Salah-Eddin Al-Batran,Nils Homann,Claudia Pauligk,Thorsten Oliver Goetze,Johannes Meiler,Stefan Kasper,Hans-Georg Kopp,Frank Mayer,Georg Martin Haag,Kim Barbara Luley,U. Lindig,Wolff Schmiegel,Michael Pohl,Jan Stoehlmacher,Gunnar Folprecht,Stephan Probst,Nicole Prasnikar,Wolfgang Fischbach,Rolf Mahlberg,Jörg Trojan,Michael Koenigsmann,Uwe M. Martens,Peter C. Thuss-Patience,Matthias Egger,Andreas Block,Volker Heinemann,Gerald Illerhaus,Markus Moehler,Michael Schenk,Frank Kullmann,Dirk M Behringer,Michael Heike,Daniel Pink,Christian Teschendorf,Carmen Löhr,Helga Bernhard,G. Schuch,Volker Rethwisch,Ludwig Fischer von Weikersthal,Jörg T. Hartmann,Michael Kneba,Severin Daum,Karsten Schulmann,Jörg Weniger,Sebastian Belle,Timo Gaiser,Fuat Oduncu,Martina Güntner,Wael Hozaeel,Alexander Reichart,Elke Jäger,Thomas Kraus,Stefan Mönig,Wolf O. Bechstein,Martin Schuler,Harald Schmalenberg,Ralf Hofheinz,Flot Aio Investigators +57 more
TL;DR: In this article, the safety and efficacy of the docetaxel-based triplet FLOT (fluorouracil plus leucovorin, oxaliplatin, and doceteaxel) as a perioperative therapy for patients with locally advanced, resectable tumours was reported.
Journal ArticleDOI
Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer
Volker Heinemann,D. Quietzsch,Frank Gieseler,Michael Gonnermann,Herbert Schönekäs,Andreas Rost,Horst Neuhaus,Caroline Haag,Michael R. Clemens,Bernard Heinrich,Ursula Vehling-Kaiser,Martin Fuchs,Doris Fleckenstein,Wolfgang Gesierich,Dirk Uthgenannt,Hermann Einsele,Axel Holstege,Axel Hinke,Andreas Schalhorn,Ralf Wilkowski +19 more
TL;DR: Results support the efficacy and safety of an every-2-weeks treatment with gemcitabine plus cisplatin as first-line chemotherapy for locally advanced or metastatic pancreatic cancer.
Journal ArticleDOI
Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer Retrospective Analyses of the CRYSTAL and FIRE-3 Trials
Sabine Tejpar,Sebastian Stintzing,Fortunato Ciardiello,Josep Tabernero,Eric Van Cutsem,Frank Beier,Regina Esser,Heinz-Josef Lenz,Volker Heinemann +8 more
TL;DR: Patients with left-sided tumors had a markedly better prognosis than those with right-sided tumor locations and a significant interaction was observed between primary tumor location and treatment for OS within the RAS wt populations of both studies in multivariable models that also included sex, prior adjuvant therapy, and BRAF mutational status.
Posted Content
The Liver Tumor Segmentation Benchmark (LiTS)
Patrick Bilic,Patrick Ferdinand Christ,Eugene Vorontsov,Grzegorz Chlebus,Hao Chen,Qi Dou,Chi-Wing Fu,Xiao Han,Pheng-Ann Heng,Jürgen Hesser,Samuel Kadoury,Tomasz Konopczynski,Miao Le,Chunming Li,Xiaomeng Li,Jana Lipkova,John Lowengrub,Hans Meine,Jan Hendrik Moltz,Chris Pal,Marie Piraud,Xiaojuan Qi,Jin Qi,Markus Rempfler,Karsten Roth,Andrea Schenk,Anjany Sekuboyina,Ping Zhou,Christian Hülsemeyer,Marcel Beetz,Florian Ettlinger,Felix Gruen,Georgios Kaissis,Fabian Lohöfer,Rickmer Braren,Julian Walter Holch,Felix Hofmann,Wieland H. Sommer,Volker Heinemann,Colin Jacobs,Gabriel Efrain Humpire Mamani,Bram van Ginneken,Gabriel Chartrand,An Tang,Michal Drozdzal,Avi Ben-Cohen,Eyal Klang,Marianne M. Amitai,Eli Konen,Hayit Greenspan,Johan Moreau,Alexandre Hostettler,Luc Soler,Refael Vivanti,Adi Szeskin,Naama Lev-Cohain,Jacob Sosna,Leo Joskowicz,Bjoern H. Menze +58 more
TL;DR: The set-up and results of the Liver Tumor Segmentation Benchmark (LITS) organized in conjunction with the IEEE International Symposium on Biomedical Imaging (ISBI) 2016 and International Conference on Medical Image Computing Computer Assisted Intervention (MICCAI) 2017 are reported.